Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study of hEGFRvIII-CD3-biscFv Bispecific T cell engager (BRiTE) in patients
diagnosed with World Health Organization (WHO) grade IV malignant glioma (MG). The primary
objective is to evaluate the safety of BRiTE alone and in combination with peripheral
autologous T-cell infusion in patients whose MG has an EGFR (epidermal growth factor
receptor) variant III (EGVRvIII) mutation.